Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Document 8265837
Document related concepts
no text concepts found
Transcript
Archivos Venezolanos de Puericultura y Pediatría ISSN: 0004-0649 [email protected] Sociedad Venezolana de Puericultura y Pediatría Venezuela de Izaguirre de Arellano, Jacqueline; Echezuría, Luis VPH Archivos Venezolanos de Puericultura y Pediatría, vol. 74, núm. 4, octubre-diciembre, 2011, pp. 159-162 Sociedad Venezolana de Puericultura y Pediatría Caracas, Venezuela Available in: http://www.redalyc.org/articulo.oa?id=367936955006 Abstract the Food and drug Administration (FdA) of usA licensed two vaccines for the prevention of vPh (human Papillomavirus) infection: Gardasil® (quadrivalent vaccine) and cervarix® (bivalent vaccine). Both vaccines are very effective in the prevention of persistent infection by serotypes 16 and 18 of vPh, two of the “high risk” vPh, which cause 70% of cervical cancers and in low percentages anal and penile cancers. Gardasil® prevents infection by serotytpes 6 and 11, which cause almost all (90%) of genital warts. this review presents the immunogenicity, efficacy, recommendations, doses, administration and commercial presentation of both vaccines. Keywords Vaccines, Gardasil, cervarix, cervical cancer, penile cancer, anal cancer genital warts. How to cite Complete issue More information about this article Journal's homepage in redalyc.org Scientific Information System Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Non-profit academic project, developed under the open access initiative
Related documents